In this issue:
Long term anti-resorptive activity after zoledronate infusion
Zoledronate causes long term remission in Paget disease
Bone-density testing interval in older women
Cortical thickness and fracture risk in women
Fracture risk in patients treated with denosumab and zoledronate
Alendronate does not reduce the incidence of total hip arthroplasty
Variations in 25-hydroxyvitamin D assays
Increasing requests for vitamin D tests lack credibility
Vitamin D dose requirements for fracture prevention
Please login below to download this issue (PDF)